Part of the Common Fund's High-Risk, High-Reward Research program, the New Innovator Award supports exceptionally creative, early-career investigators who propose innovative, high-impact projects with no preliminary data required.
Mapping Body Language
Sandeep Datta, a 2010 New Innovator, developed new computational techniques that read complex patterns of behavior and body movements of mice and organizes them into units. The techniques eliminates the need for human observers (and their biases) and will lead to new insight into how the brain creates behavior and how that process is disrupted in disease. (View the video abstract )
Extending Youth in Worms
Michael Petrascheck, a 2011 New Innovator, used an antidepressant drug to prolong life in roundworms by extending young adulthood. The drug fights against transcriptional drift and raises the possibility of using drugs to delay the onset of age-related disease.
New Model Shows Maternal Immune Cells Protect Against Severe Cytomegalovirus Disease
Sallie Permar, a 2012 New Innovator, developed a nonhuman primate model of congenital cytomegalovirus transmission (the leading infectious cause of childhood hearing loss and brain damage) and used the model to demonstrate the important role the maternal immune system plays in disease severity and fetal loss. The model opens the pathway for clinically-relevant congenital CMV vaccine development and research.
|• Early stage investigator with no R01 or equivalent NIH grant
• Within 10 years of doctoral degree or medical internship/residency
• No preliminary data required
• Awards up to $300K per year for up to 5 years
• More information
Keeping Worms Young
Michael Petrascheck, a 2011 New Innovator, was featured in The Guardian and IFL Science! for his use of an antidepressant drug to prolong life in roundworms by extending young adulthood. The drug fights against transcriptional drift and raises the possibility of using drugs to delay the onset of age-related disease.
Edward Boyden and Karl Deisseroth Receive 2016 Life Sciences Breakthrough Prize
Edward Boyden (2007 New Innovator, 2012 and 2013 Transformative Research, and 2013 Pioneer awardee) and Karl Deisseroth (2005 Pioneer and 2012 Transformative Research awardee) were awarded $3 million each for the 2016 Breakthrough Prize in Life Sciences.
|Child with Drug-Resistant TB Successfully Treated
Sanjay Jain, a 2009 awardee, successfully treated a 2-year old child with a highly virulent form of tuberculosis known as extensively drug-resistant (XDR) TB. The case is the first detailed account of a young child in the United States being diagnosed and treated for XDR TB. The case is published online in the November 16 edition of The Lancet Infectious Diseases. Read more at the Washington Post .